Pathology: mNSCLC - L1 - PDL1 positive;
mNSCLC - L1 - PDL1 positive | |||||
KEYNOTE-042 (PDL1>1%), 2019 | KEYNOTE-024 (PDL1>50%), 2016 | KEYNOTE-042 (PDL1>50%), 2019 | KEYNOTE-042 (PDL1>20%), 2019 | ||
pembrolizumab alone | 4 | T1 | T1 | T1 | T1 |
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 |